Last reviewed · How we verify
Nonvalvular atrial fibrillation
Approved treatments
- Xarelto · University Hospital, Montpellier
- Xarelto · Johnson & Johnson
Selective FXa inhibitor that decreases thrombin generation without requiring cofactors.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Nonvalvular atrial fibrillation patent landscape — cliff calendar, originator estates, attackable patents
- Nonvalvular atrial fibrillation treatment landscape brief
- Nonvalvular atrial fibrillation treatment updates RSS
Frequently asked questions about Nonvalvular atrial fibrillation
What drugs treat Nonvalvular atrial fibrillation?
Tracked treatments include Xarelto.
What is the treatment for Nonvalvular atrial fibrillation?
Standard treatment for Nonvalvular atrial fibrillation includes Xarelto. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Nonvalvular atrial fibrillation patent cliff · Nonvalvular atrial fibrillation CI report
- Treatment: Xarelto · University Hospital, Montpellier
- Treatment: Xarelto · Johnson & Johnson
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing